LLY compared with IBIO: revenue, margins and what each company keeps, and the suppliers and customers both name

LLYELI Lilly & Co

Mkt capRevenueRevenue

IBIOiBio, Inc.

Mkt capRevenueRevenue

Compare

LLYELI Lilly & Co

IBIOiBio, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Revenue flow

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

LLYELI Lilly & Co

1,382.22▼−2.52%

Mkt cap$1.3TRevenue$24.4BQ3 FY26Revenue$65.2BFY25

IBIOiBio, Inc.

0.72▼−9.50%

Regular sessionNov 5 '26

Mkt cap$51.4MRevenue$100,000Q1 FY26Revenue—

Compare

Regular sessionNov 5 '26

LLYELI Lilly & Co

IBIOiBio, Inc.

1,382.22▼−2.52%

Price

0.72▼−9.50%

$1.3T

Mkt cap

$51.4M

Q3 FY26$24.4B

Revenue

$100,000Q1 FY26

FY25$65.2B

Revenue

—

LLY1,382.22▼−2.52%vsIBIO0.72▼−9.50%Regular sessionNov 5 '26

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Price

Supply-chain overlap

Revenue flow

IBIO: latest quarter is a loss; flow not drawable.Method ›

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only LLY 29

MCKMcKessoncustomer

CAHCardinal Healthcustomer

VEEVVeeva Systemssupplier

UTHRUnited Therapeuticscustomer

25 more · LLY chain ›

Shared 0

No shared counterparties.

Only IBIO 16

TWSTTwist Biosciencesupplier

—AstralBiounlistedsupplier

—Chardanunlistedsupplier

—

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

Lonza Sales

unlistedsupplier

12 more · IBIO chain ›

Price

rebased to 0%

LLY, solidIBIO, dashed